Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
Completed · Phase 3 · Has a placebo group
Conditions studied: Healthy
In brief
The primary objective of the study is to evaluate whether premedication with 325 mg microcoated aspirin (ASA) tablet or a slow-titration dosing schedule of BG00012 reduces the incidence and severity of flushing and GI events following oral administration of BG00012 dosed at 240 mg twice a day (BID) in healthy volunteers. The secondary objective of this study is to evaluate the safety and tolerability of BG00012 when administered orally as a 240 mg BID dose regimen with and without 325 mg ASA premedication or following a slow-titration dosing schedule in healthy volunteers.
Key facts
- Study ID
- NCT01568112
- Run by
- Biogen
- People needed
- 173
- Starts
- 2012-04-01
- Expected to finish
- 2012-10-01
- Last updated by the study team
- 2016-06-13
Who can join
Age: 25 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Research Site — Saint Paul, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.